Quest Diagnostics Inc(NYSE:DGX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 21, 2016. Company reported revenue of $1.91B. Analysts estimated a revenue of $1.91B. Earnings per share were $1.34. Analysts had estimated an EPS of $1.32.
In a different note, On Jun 24, 2016, Jyske Bank said it Downgrades its rating on Quest Diagnostics Inc. The shares have been rated ‘Sell’ by the firm.
Quest Diagnostics Inc (DGX) made into the market gainers list on Wednesdays trading session with the shares advancing 0.49% or 0.41 points. Due to strong positive momentum, the stock ended at $83.56, which is also near the day’s high of $83.86. The stock began the session at $83.5 and the volume stood at 9,64,586 shares. The 52-week high of the shares is $83.9658 and the 52 week low is $59.655. The company has a current market capitalization of $11,820 M and it has 14,14,57,180 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jun 1, 2016, Catherine T. Doherty (SVP, Clin. Franchise Solutions) sold 47,334 shares at $77.27 per share price.Also, On May 16, 2016, Jenne K Britell (director) sold 8,000 shares at $75.68 per share price.On May 11, 2016, Everett Cunningham (SVP, Commercial) sold 56,312 shares at $76.24 per share price, according to the Form-4 filing with the securities and exchange commission.
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business consists of two parts develops and delivers diagnostic testing information and services to patients physicians health plans hospitals accountable care organizations (ACOs) integrated delivery networks (IDNs) other commercial laboratories patients and other customers. Diagnostics Information Services business also provides diagnostic information services which includes providing clinical testing services such as routine testing gene-based and esoteric testing anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses including central laboratory testing for pharmaceutical and medical device clinical trials risk assessment services diagnostic products and healthcare information technology.